Orange Ventures has invested in French health-tech startup Biolevate, while Orange Business is partnering with the company to expand the use of trusted agentic AI across pharmaceutical research, clinical development, and regulatory processes.
The investment was made as part of Biolevate’s latest financing round and is aimed at supporting the company’s growth in healthcare and life sciences.
Orange said the move also forms part of its broader effort to support the French technology ecosystem and develop trusted digital solutions combining AI, security, and operational value.
Through Orange Ventures, the company invests in high-growth businesses that can create technological, commercial, and strategic synergies with the Group, particularly across data and AI, digital enterprise, and e-health.
Biolevate is also part of the 2025 French Tech 2030 promotion and has been supported by Future4Care, the European digital health ecosystem co-founded by Orange.
From AI Experimentation to Operational Adoption
Biolevate develops an agentic AI platform designed to capture, structure, and operationalize validated scientific and regulatory knowledge.
According to the company, its technology has enabled up to 50% faster time-to-market for selected pharmaceutical processes.
Its AI agents are designed to support work across the healthcare innovation lifecycle, including drug research and development, clinical operations, market access, health technology assessments, literature reviews, and regulatory activities.
Alongside the Orange Ventures investment, Orange Business will work with Biolevate to combine these agentic AI capabilities with Enovalife’s clinical research, data, AI, and digital transformation expertise.
Enovalife, an Orange Business affiliate, works with pharmaceutical companies across clinical and medical research, data and AI, and health data management.
The partnership will focus on clinical development use cases where automation and operational integration can support pharmaceutical companies as they move beyond AI proofs of concept.
These areas include clinical trial protocol development, clinical study reports, and regulatory bridging, where documentation and compliance requirements often need to be adapted across different jurisdictions.
Joel Belafa, CEO of Biolevate, said:
“Our mission is to reduce the time between a potentially life-saving discovery and the moment it reaches patients. We do this through knowledge-driven automation for life sciences, paving the way for faster therapies through trusted AI agents. Orange Ventures’ investment in our second financing round, together with our strategic partnership with Orange Business, Enovalife and Future4Care, creates a strong opportunity to scale this impact for life sciences organizations in France, Europe and globally.”
Claire Scotton, Vice President, Healthcare and Life Sciences at Orange Business, added:
“The priority for pharmaceutical R&D organizations is no longer simply to test AI, but to deploy it at scale in ways that create value for teams and fit their operations. Biolevate brings a highly relevant approach to knowledge-driven automation for life sciences and trusted AI agents. Enovalife contributes deep sector knowledge and proven integration capabilities. Together we aim to help customers accelerate their AI transformation, improve the consistency of clinical and regulatory processes, and keep human expertise at the heart of innovation.”
Inside Telecom provides you with an extensive list of content covering all aspects of the Tech industry. Keep an eye on our News section to stay informed and updated with our daily articles.
